Q1 EPS Estimate for Larimar Therapeutics Reduced by Analyst

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Equities research analysts at William Blair reduced their Q1 2025 earnings per share (EPS) estimates for Larimar Therapeutics in a research note issued to investors on Monday, March 24th. William Blair analyst M. Minter now anticipates that the company will earn ($0.46) per share for the quarter, down from their previous forecast of ($0.35). The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. William Blair also issued estimates for Larimar Therapeutics’ Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.53) EPS, Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($2.01) EPS, Q1 2026 earnings at ($0.52) EPS, Q2 2026 earnings at ($0.51) EPS, Q3 2026 earnings at ($0.52) EPS, Q4 2026 earnings at ($0.52) EPS and FY2026 earnings at ($2.07) EPS.

Larimar Therapeutics (NASDAQ:LRMR) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.16).

Several other analysts have also recently commented on the company. Truist Financial began coverage on Larimar Therapeutics in a report on Wednesday, January 29th. They issued a “buy” rating and a $18.00 target price on the stock. Robert W. Baird dropped their target price on shares of Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating on the stock in a report on Tuesday. HC Wainwright lifted their price objective on Larimar Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Guggenheim restated a “buy” rating and set a $26.00 target price on shares of Larimar Therapeutics in a research report on Tuesday. Eleven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Larimar Therapeutics has an average rating of “Buy” and an average target price of $20.22.

Larimar Therapeutics Trading Down 2.6 %

Shares of LRMR opened at $2.25 on Thursday. The company has a market capitalization of $143.57 million, a PE ratio of -1.96 and a beta of 0.99. The stock’s 50-day moving average price is $3.11 and its two-hundred day moving average price is $5.18. Larimar Therapeutics has a 12 month low of $2.19 and a 12 month high of $11.20.

Hedge Funds Weigh In On Larimar Therapeutics

Institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets acquired a new position in Larimar Therapeutics during the fourth quarter worth $25,000. Algert Global LLC acquired a new position in Larimar Therapeutics during the 4th quarter valued at about $47,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Larimar Therapeutics in the fourth quarter valued at approximately $52,000. Graham Capital Management L.P. purchased a new position in shares of Larimar Therapeutics during the fourth quarter valued at approximately $54,000. Finally, ProShare Advisors LLC bought a new stake in Larimar Therapeutics during the fourth quarter worth $58,000. 91.92% of the stock is owned by institutional investors and hedge funds.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.